SCHEDULE: Sphera Funds Discloses 5.33% Stake in Tenax Therapeutics

Sphera Funds Management Ltd. and its affiliates have reported a beneficial ownership of 5.33% in Tenax Therapeutics, Inc. common stock as of August 17, 2026.

Summary

• Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd., and Sphera Global Healthcare Management LP have jointly filed a Schedule 13G.
• The filing indicates a beneficial ownership of 1,993,496 shares of Tenax Therapeutics, Inc. common stock.
• This ownership represents 5.33% of the total outstanding shares.
• The percentage is based on 37,423,917 shares outstanding as of July 28, 2026, as reported by Tenax Therapeutics in its Form 10-Q filed on July 31, 2026.
• The reporting persons are organized under the laws of Israel.
• The filing asserts that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting ownership stakes rather than significant company performance or strategic shifts.

Positives

• Significant institutional ownership reported by Sphera Funds, indicating confidence in Tenax Therapeutics.
• Clear disclosure of ownership stake, providing transparency to the market.

Negatives

• The filing does not contain financial performance data or strategic updates, limiting insight into the company's operational health.
• The nature of the ownership (investment management delegation) adds a layer of complexity to direct control assessment.

Risks

• Potential for future changes in ownership by Sphera Funds, which could impact stock price and liquidity.
• The filing does not provide details on the investment strategy or rationale behind acquiring this stake.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the company.

Management Comments

• This Statement shall not be construed as an admission by any of the reporting persons that it is the beneficial owner of any of the securities covered by this statement, and each reporting person disclaims beneficial ownership of any such securities.
• Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the reporting persons and other entities named in this Schedule 13G disclaims the existence of any such group.

Industry Context

StockSavvy.ai notes that significant ownership filings by investment firms like Sphera Funds are common in the biotechnology and healthcare sectors, often indicating a belief in the company's potential or a strategic investment position.

Stakeholder Impact

• Shareholders: Increased institutional ownership may signal investor confidence but also potential for future block trades impacting liquidity.
• Management: The filing provides transparency on a significant shareholder, which is standard practice.

Next Steps

• Monitor future filings from Sphera Funds Management Ltd. for any changes in their ownership stake.
• Observe Tenax Therapeutics' operational and financial performance to assess the underlying value of the company.

Key Dates

Keywords

Tenax Therapeutics, Sphera Funds Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Healthcare, Biotechnology, SEC Filing